Dawes J, James K, Lane D A
Heart Research Institute, Camperdown, NSW, Australia.
Biochemistry. 1994 Apr 12;33(14):4375-83. doi: 10.1021/bi00180a035.
A murine monoclonal antibody (MAb) raised against a covalent antithrombin-heparin complex was used to probe the conformational change resulting when the serpin antithrombin binds to heparin. This MAb completely inhibited the progressive activity of antithrombin against thrombin. However, although the MAb remained bound to antithrombin in the presence of heparin, it did not significantly inhibit heparin cofactor activity against thrombin, and increasing concentrations of the antithrombin-binding pentasaccharide progressively unblocked the inhibitory action of the MAb. The MAb bound to antithrombin without affecting either heparin-binding affinity or heparin-induced fluorescence enhancement, and it did not convert antithrombin from inhibitor to substrate. The MAb failed to interact with reduced and S-carboxymethylated antithrombin, indicating the conformational nature of its epitope. Antithrombin variants with N-terminal substitutions (Arg47-->Cys or His, Leu99-->Phe, Arg129-->Gln) modifying heparin binding, and C-terminal substitutions affecting the reactive site (Arg393-->Cys) or resulting in substrate-variant antithrombin (Ala384-->Pro), were all recognized normally, as were normal reactive site cleaved antithrombin and the thrombin-antithrombin complex. However, interaction of the MAb with antithrombin was reduced by several substitution mutations (Phe402-->Cys, Phe402-->Ser, Phe402-->Leu, Ala404-->Thr, Pro407-->Thr) in the 402-407 sequence which codes for amino acid residues of strand 1C and the polypeptide leading to strand 4B. Pro429-->Leu also blocks recognition [Olds et al. (1992) Blood 79, 1206-1212], and this residue is believed to be spatially approximated to strand 1C.(ABSTRACT TRUNCATED AT 250 WORDS)
一种针对共价抗凝血酶 - 肝素复合物产生的鼠单克隆抗体(MAb)被用于探究丝氨酸蛋白酶抑制剂抗凝血酶与肝素结合时所导致的构象变化。该单克隆抗体完全抑制了抗凝血酶对凝血酶的渐进性活性。然而,尽管在肝素存在的情况下单克隆抗体仍与抗凝血酶结合,但它并未显著抑制肝素辅因子对凝血酶的活性,并且抗凝血酶结合五糖浓度的增加逐渐解除了单克隆抗体的抑制作用。该单克隆抗体与抗凝血酶结合而不影响肝素结合亲和力或肝素诱导的荧光增强,并且它不会将抗凝血酶从抑制剂转变为底物。该单克隆抗体未能与还原型和S - 羧甲基化抗凝血酶相互作用,表明其表位的构象性质。具有修饰肝素结合的N端取代(Arg47→Cys或His,Leu99→Phe,Arg129→Gln)以及影响反应位点(Arg393→Cys)或产生底物变体抗凝血酶(Ala384→Pro)的C端取代的抗凝血酶变体,均能被正常识别,正常反应位点裂解的抗凝血酶和凝血酶 - 抗凝血酶复合物也是如此。然而,单克隆抗体与抗凝血酶的相互作用因402 - 407序列中的几个取代突变(Phe402→Cys,Phe402→Ser,Phe402→Leu,Ala404→Thr,Pro407→Thr)而降低,该序列编码1C链的氨基酸残基以及通向4B链的多肽。Pro429→Leu也会阻断识别[奥尔兹等人(1992年),《血液》79,1206 - 1212],并且该残基被认为在空间上与1C链接近。(摘要截断于250字)